Tag:
Quest Diagnostics
Latest Headlines
Latest Headlines
Quest snags Philips Healthcare head as new CEO
Stephen Rusckowski (pictured), who has served as CEO of Philips Healthcare since 2006, will join Quest Diagnostics May 1.
Quest to partner with Israeli biotech on MAP test
Quest Diagnostics ( $DGX ) is teaming up with Israel's RedHill Biopharma on a diagnostic test for mycobacterium avium paratuberculosis bacteria in the blood of Crohn's disease patients. RedHill is
Quest's companion diagnostic confronts Tysabri brain infection risk
It's a vexing problem that certain drugs with enormous benefit can also carry significant health risk. Case in point: Some patients who take the multiple sclerosis drug Tysabri experience improved
Quest begins search for CEO
Quest Diagnostics' ( $DGX ) board is trying to find a successor to outgoing Chairman and CEO Surya Mohapatra, forming a committee and engaging a leading executive recruitment firm to aid in the search.
Quest Diagnostics completes Athena buy
Quest Diagnostics has completed its previously announced acquisition of Athena Diagnostics, an esoteric laboratory specializing in genetic testing for neurological disorders. Worcester, MA-based
Quest Diagnostics snags Celera in $344M buyout
Quest Diagnostics is snapping up Celera--along with its expertise in genetics and biomarkers--for $344 million in cash. "Our discovery and validation of new biomarkers has exceeded our capacity to
ALSO NOTED: Quest Diagnostics buys HemoCue; Affymax pockets $10M milestone;Pozen to file response on Trexima; and much more...
> Quest Diagnostics has acquired Sweden's HemoCue, from the private equity firm EQT II for $420 million in cash. Release
> Affymax has nailed a $10 million milestone payment from Takeda. Release
> The FDA has called MGI Pharma's ad for a …
ALSO NOTED: Wyeth releases Tygacil data; Eurand inks deal with GSK; and much more...
> Wyeth has released data from a Phase III trial of Tygacil that shows a statistically similar ability to treat community acquired pneumonia as an existing therapy. Tygacil cured 89.7 percent of patients compared to 86.3 percent for levofloxacin. One infectious disease expert says that new therapies for CAP are needed as antibiotic-resistant strains emerge. …
ALSO NOTED: QuatRx pulls IPO; GSK's Avandamet gains new approval; and much more...
> QuatRx Pharmaceuticals has yanked its IPO, citing market conditions. Release
> The FDA has given GlaxoSmithKline's Avandamet approval as a front-line therapy for Type 2 diabetes. It won approval as a second-line therapy for some diabetes patients in 2002. Report
> Athenagen and Zapaq, both …
DEALS: AstraZeneca buys CAT for $1.3B
AstraZeneca buys CAT for $1.3B
